Compare GBLI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBLI | EDIT |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.7M | 432.8M |
| IPO Year | 2010 | 2016 |
| Metric | GBLI | EDIT |
|---|---|---|
| Price | $28.60 | $3.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.30 |
| AVG Volume (30 Days) | 3.0K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $450,098,000.00 | $31,937,000.00 |
| Revenue This Year | $14.23 | N/A |
| Revenue Next Year | $9.68 | N/A |
| P/E Ratio | $27.24 | ★ N/A |
| Revenue Growth | 2.02 | ★ 132.64 |
| 52 Week Low | $24.28 | $1.66 |
| 52 Week High | $30.52 | $4.54 |
| Indicator | GBLI | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 61.54 |
| Support Level | $27.66 | $2.74 |
| Resistance Level | $29.16 | $3.65 |
| Average True Range (ATR) | 0.89 | 0.20 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 89.07 | 75.62 |
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.